The British Dietetic Association's new evidence review pinpoints specific probiotic strains alongside psyllium and magnesium oxide as clinically effective interventions for chronic constipation, which impacts roughly 10% of adults globally. The guidelines represent a significant shift toward strain-specific recommendations rather than broad probiotic categories, suggesting that therapeutic efficacy depends on precise bacterial subspecies rather than general lactobacilli or bifidobacteria supplementation. This targeted approach addresses a major gap in gastroenterology, where constipation management has traditionally relied on fiber and laxatives with inconsistent results. The inclusion of specific strains in professional dietary guidelines signals growing confidence in microbiome-based therapeutics, potentially offering relief for millions who don't respond adequately to conventional treatments. However, the effectiveness likely varies based on individual microbiome composition and underlying causes of constipation. While promising for functional constipation, these interventions may be less effective for medication-induced or structural causes. The guidelines could accelerate adoption of precision probiotic therapy in clinical practice, though long-term safety data and optimal dosing protocols remain areas for continued research.